The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1107
June 25, 2001
View Complete Issue         Table of Contents 2019 
Galantamine (Reminyl) for Alzheimer's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Galantamine (Reminyl) for Alzheimer's Disease
June 25, 2001 (Issue: 1107)
Galantamine hydrobromide (Reminyl), a tertiary alkaloid and phenanthrene derivative extracted from daffodil bulbs, is now being marketed for oral treatment of mild to moderate Alzheimer's disease. Galantamine is the fourth acetylcholinesterase...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Galantamine (Reminyl) for Alzheimer's Disease
Article code: 1107a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.